Icotinib

• Description :

  Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• Product Name Alternative :

  BPI-2009

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  EGFR

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/icotinib.html

• Concentration :

  10mM

• Purity :

  99.96

• Solubility :

  DMSO : ≥ 155 mg/mL

• Smiles :

  C#CC1=CC(NC2=C(C=C(OCCOCCOCCO3)C3=C4)C4=NC=N2)=CC=C1

• Molecular Formula :

  C22H21N3O4

• Molecular Weight :

  391.42

• Precautions :

  H302

• References & Citations :

  [1]Tan F, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012 May;76 (2) :177-82.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  EGFR/ErbB1/HER1

• Citation 01 :

  Breast Cancer Res Treat. 2025 Jun;211 (2) :467-478.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Clin Chim Acta. 2022 Feb 15:527:1-10.|Eur J Pharmacol. 2019 May 5:850:141-149.|J Pharm Biomed Anal. 2023 May 10:228:115275.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Biochem Pharmacol. 2016 Dec 1:121:67-77.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Science. 2017 Dec 1;358 (6367) :eaan4368.

• CAS Number :

  [610798-31-7]